tbuckley/cabot-search huggingface dataset:
Bone abnormalities in male germ-cell cancer survivors
Authors: P. M. Willemse, L. van Wulften, A. Q. van Steijn, N. A. Hamdy, S. Osanto
Journal: Journal of Clinical Oncology (2007)

5053 Background: Survival of men with testicular cancer is long due to successful therapeutic intervention, which usually includes orchidectomy. Therefore, we studied the prevalence of osteoporosis in a single center cohort of long term survivors of germ cell cancer. Methods: In a cross-sectional study design, we studied 186 male patients with a mean age of 39.6 years (range 18.1–66.8), who were treated between 1977 and 2006 for germ cell cancer. 181 (97.3%) patients underwent an unilateral, 3 (1.6%) a bilateral orchidectomy and in 2 (1.1%) patients no orchidectomy but retroperitoneal or mediastinal tumor biopsy was performed to confirm the diagnosis. 141 (75.8%) patients received cisplatin-based combination chemotherapy for metastases or primary extra-gonadal tumor at a mean age of 29.4 years (range 14.2- 62.6). Between 2003 and 2006, bone mineral density (BMD) was measured at the lumbar spine and femoral neck by DXA and Z-scores calculated. Vertebral deformities were evaluated by a semi-quantitative measurement on lateral x-rays of the spine. Non-vertebral fractures were evaluated by questionnaire and confirmed by x-ray. All patients had normal total testosterone, estradiol, parathyroid hormone, 25(OH)- vitamin D and 1,25(OH) 2 -vitamin D concentrations, evaluated by fasting blood samples. Results: BMD was low in 59 (31.7%) patients; 46 (24.7%) patients had Z-scores between -1 and -2 SD, while thirteen (7.0%) had Z-scores below -2 SD. Vertebral deformities were present in 57 of 151 (37.7 %) evaluated patients, sixteen of whom also had low BMD. There was no relationship between vertebral deformities and either age, chemotherapy or testosterone/estradiol levels. No correlation was found between vertebral deformities and low BMD. Eight of 114 (7.0%) patients who responded to the questionnaire had non-vertebral fractures at a mean age of 44.9 years (range 33.1–54.2); 1–17 years after the initial diagnosis of testicular cancer. Conclusions: More than one third of the eugonadal male survivors of germ cell cancer survivors have vertebral abnormalities which are not related to age, chemotherapy or genital hormone concentrations. The underlying mechanism remains unknown. This high prevalence of bone abnormalities indicates that screening should be advocated in all germ cell cancer survivors. No significant financial relationships to disclose.
Microbiology of acute periodontal infection in myelosuppressed cancer patients.
Authors: D E Peterson, G E Minah, C D Overholser, J B Suzuki, L G DePaola, D M Stansbury, L T Williams, S C Schimpff
Journal: Journal of Clinical Oncology (1987)

This study characterized the subgingival microbial flora associated with 27 acute exacerbations of preexistent periodontal disease in 24 patients with chemotherapy-induced myelosuppression. All but two acute periodontal infections developed at low granulocyte levels (less than 1,000/microL). Suspected pathogens were detected in high concentrations in subgingival plaque specimens in 17 episodes of acute periodontal infection; a single pathogen was recovered in ten acute infections, and more than one pathogen was recovered in seven acute infections. Staphylococcus epidermidis, Candida albicans, S aureus, and Pseudomonas aeruginosa predominated, with combinations of these detected in some patients. Concomitant bacteremias developed in two of these patients. The subgingival microflora associated with ten acute periodontal infections was characterized by predominantly indigenous microorganisms, which in nine episodes were in abnormal proportions compared with microbial profiles in noncancer patients with similar degrees of periodontal disease. These data demonstrate that pathogens normally associated with infections in myelosuppressed cancer patients, as well as indigenous oral flora, are associated with acute periodontal infections during granulocytopenia. This finding is important, since this body site has not commonly been recognized as a source for acute infection in these patients.
Cardiovascular abnormalities in long-term survivors of childhood malignancy.
Authors: S E Lipshultz, S E Sallan
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.7.1199 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8315417 Cardiovascular abnormalities in long-term survivors of childhood malignancy. S E LipshultzxS E LipshultzSearch for articles by this author , S E SallanxS E SallanSearch for articles by this author https://doi.org/10.1200/JCO.1993.11.7.1199 First Page PDF © 1993 by American Society of Clinical Oncology
One in four GP appointments can be avoided, says report
Authors: Jacqui Wise
Journal: BMJ (2015)

More than a quarter of GP appointments could potentially have been avoided if wider use were made of other primary care staff, more coordination between GPs and hospitals, and better use of technology, a new report argues.1

The report, by the NHS Alliance and the Primary Care Foundation, said that much of GPs’ time was taken up with rearranging hospital appointments and chasing test results from hospitals. It called for the booking and rearranging of hospital appointments to be made simpler, without the patient needing to go back to the GP.

Commissioned by NHS England, the report involved an audit of 5128 GP consultations across England. Overall 27% of GP appointments were …
Geographical Variations in Mortality From Cancer in Iceland, With Particular Reference to Stomach Cancer2
Authors: Julius Sigurjonsson
Journal: JNCI Journal of the National Cancer Institute (1966)

In the study of geographical distribution of deaths from cancer in Iceland, an attempt was made to check the comparability of recording in the different areas. Because of underrecording, to a varying extent, of cancer in old persons, deaths at ages 0–64 formed a better basis for comparison of cancer mortality than deaths at all ages. Mortality from stomach cancer was particularly high in the northwestern part of Iceland, the standard mortality ratio for ages up to 64 being 139.5 in 1931–60. In Reykjavik the ratio was 84.7. In both instances the deviation from expected mortality was of considerable statistical significance. Corresponding, but less marked, differences emerged for all cancer of the digestive organs, and the peritoneum. Deaths from all cancers, however, did not show significant variations. The standard mortality ratios for ages 0–64 were somewhat higher for stomach cancer in rural areas than in urban, although no clear-cut urban-rural difference was revealed by the ratios for all ages. Urban-rural differences in mortality from all cancers were not apparent.
Varicella-Zoster Virus in Giant Cell Arteritis—Reply
Authors: Maria A. Nagel, Teresa White, Don Gilden
Journal: JAMA Neurology (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Health secretary accuses BMA of “utter irresponsibility” over junior doctors’ contract
Authors: Gareth Iacobucci
Journal: BMJ (2015)

England’s health secretary, Jeremy Hunt, has stepped up his rhetoric against the BMA in the ongoing dispute over junior doctors’ contracts.

In his keynote speech to the Conservative Party conference in Manchester on 6 October, Hunt accused the association of scaremongering by portraying the message that the government wanted to cut doctors’ pay and said that it was “utterly irresponsible” to do so.

The row over the government’s plan to impose a new deal on junior doctors from August …
Triple-negative breast cancer in Hong Kong Chinese patients
Authors: J. Tsang, T. L. Lai, D. H. Lau, G. K. Au, D. T. Chua
Journal: Journal of Clinical Oncology (2009)

e22127 Background: There is increasing data showing that breast cancer is a heterogeneous disease which should be assessed separately in different populations, as it differs substantially between Chinese and Caucasian women. Triple-negative breast tumours which are negative for ER, PR and HER-2 neu receptors are associated with younger age at presentation, tumour of higher grade with larger size and a poorer prognosis. There is recent suggestion that the prognostic outlook of Chinese triple-negative breast cancers might be somewhat different from those in the Western population, but few studies have attempted to understand the role of ethnic factor in the triple-negative entity. Methods: We conducted a preliminary retrospective comparison of 170 Hong Kong Chinese primary breast cancer patients seen as new cases during January 2004 and December 2004 in a teaching hospital. Clinico-pathological features of triple-negative tumours were compared to their non-triple-negative counterpart. Results: Triple negative breast cancer accounted for 12.4% of all breast cancer patients seen in the year of 2004 (n = 21). It is associated with more cancers with grade 3 tumour (68.4% vs 36.8%; p = 0.02) but there was no statistically difference between the age of presentation, tumour size, extensive intraductal component, lymph node status and rate of local relapse or metastasis after adjuvant therapy. Subset analysis further revealed that when triple negative breast cancer patients (n = 21) were compared to the HER-2 positive patients (n = 40) in the studied population, HER-2 positive patients were still associated with higher proportion of node positive disease (57.5% vs 30.0%; p = 0.04). Disease free survival and overall survival were not studied due to limited follow-up time. Conclusions: Our preliminary findings suggested that Hong Kong Chinese triple-negative breast cancers are associated with a more favourable outlook and might behave differently when compared to their Western counterpart. Further large-scale study of the ethnic factor with long-term follow-up is warranted. No significant financial relationships to disclose.
Defective Cytotoxic T-Cell Generation in Moloney Murine Sarcoma Virus-Infected A/Sn Mice23
Authors: Susanne Becker, Eva Klein
Journal: JNCI Journal of the National Cancer Institute (1980)

Journal Article Defective Cytotoxic T-Cell Generation in Moloney Murine Sarcoma Virus-Infected A/Sn Mice Get access Susanne Becker, Susanne Becker 4Department of Tumor Biology, Karolinska Institute S-10401, Stockholm, Sweden. 5Department of Medical Microbiology, University of Linkoping, Linkoping, Sweden. 6Address reprint requests to Dr. Becker at her present address: Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina, Chapel Hill, N.C. 27514. Search for other works by this author on: Oxford Academic PubMed Google Scholar Eva Klein Eva Klein 4Department of Tumor Biology, Karolinska Institute S-10401, Stockholm, Sweden. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 65, Issue 4, October 1980, Pages 811–816, https://doi.org/10.1093/jnci/65.4.811 Published: 01 October 1980 Article history Received: 10 December 1979 Accepted: 21 April 1980 Published: 01 October 1980
Pilot trial of decision aids for patients with advanced breast, lung, colorectal, or prostate cancer.
Authors: L. A. Dow, T. J. Smith, E. A. Virago, R. K. Matsuyama, J. L. Khatcheressian, L. J. Lyckholm
Journal: Journal of Clinical Oncology (2010)

9108 Background: Most cancer patients who will die from their disease do not have an explicit discussion about prognosis and treatment options despite most wanting such information. Oncologists do not want to take away hope. Few decision aids have been developed to assist these difficult discussions. Methods: We developed decision aids for people with advanced cancer facing first, second, third, and fourth line chemotherapy. We recruited 27 patients from our urban oncology clinic after gaining the permission of their treating oncologist. The decision aid gave chance of cure (always none), response rates, survival data, toxicity, and ways to transition to end of life planning. We measured knowledge and attitudes before and after the intervention. GO8 LM0095259. Results: 26 of 27 patients completed the exercise. Mean age 63; 56% female, 56% married, 44% white, 56% black, 67% HS diploma or more, 67% incomes <$35,000. Most patients thought a person with their advanced cancer could be cured which was reduced after the Decision Aid. 60% thought chemotherapy would shrink their cancer by half. No distress was noted and some found that their survival might be better than they expected. Hope did not change. The majority found the information helpful to them and almost all wanted to share the information with their family and physicians. Conclusions: It is possible to give patients with incurable illness their prognosis, treatment options, and options for improving end of life care without causing distress or lack of hope. Some but not all patients can understand that they cannot be cured. Almost all find the information helpful and want to share it with doctors and family. Research is needed to test the findings in a larger sample online and measure the longer term outcomes of truthful information on quality of life, quality of care, and costs. Patient knowledge before and after decision aid Pre Post Can this person with cancer in the bones and lymph nodes be cured by medical treatment? Yes=14 Yes=8 No=11 No=17 52%→ 27%, NS Herth Hope Index (0-48, 48=most hopeful) 44.2 44.8, +0.63, NS Distress observed by interviewer, nurse, or oncologist No No Was this helpful to you? Yes 74% Will you share this information? Yes 93% No significant financial relationships to disclose.
Abstract 13784: Single Cell Profiling Enables Surface Marker Discovery in Cardiac Progenitor Cells
Authors: Laura Tarnawski, Iain Macaulay, Sten Erik W Jacobsen, Sean M Wu, Stefan Jovinge
Journal: Circulation (2013)

In tissues like the heart, a complex and heterogeneous organ, it is often difficult to purify and characterize different cell types. Many of the intracellular biomarkers for different populations a...
Cancer-related anorexia/cachexia (CACS) and oxidative stress (OS): A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2
Authors: G. Mantovani, A. Macciò, C. Madeddu, G. Gramignano, M. R. Lusso, E. Massa, G. Astara, R. Serpe, M. Mocci, S. Perboni
Journal: Journal of Clinical Oncology (2004)

8103 Background: CACS/OS play a key role in the progression and outcome of cancer. The conventional treatment based on progestagens shows limited efficacy. An important role may be played by a pharmaco-nutritional support containing EPA. Patients and Methods: A phase II non randomized study has been designed to evaluate the efficacy and tolerability of an innovative approach consisting of: diet with high polyphenols content (400 mg), oral pharmaco-nutritional support enriched with n-3 PUFA (EPA, DHA) 2 cans (237 ml each)/day, medroxyprogesterone acetate 500 mg/day, antioxidant treatment (alpha lipoic acid 300 mg/day + carbocysteine lysine salt 2.7 g/day + vitamin E 400 mg/day + vitamin A 30000 IU/day + vitamin C 500 mg/day), selective COX-2 inhibitor Celecoxib 200 mg/day. The treatment is administered for 16 weeks. The planned accrual is 40 patients. The 1) clinical (stage and ECOG PS), 2) nutritional (Lean Body Mass, LBM, appetite (VAS), resting energy expenditure), 3) laboratory (serum proinflammatory cytokines, CRP and leptin and blood levels of reactive oxygen species (ROS) and antioxidant enzymes) and 4) quality of life (EORTC QLQ-C30, EQ-5D and EQ-5Dvas) parameters have been evaluated. Results: 29 patients have been enrolled (16 head and neck, 4 breast; all stage IV). 22 patients are evaluable: 13 patients after 4 months, 17 after 2 months and 22 after 1 month of treatment. As for LBM a mean increase of 1.3 kg (+5.7%) after 1 month (p=ns), 1.4 kg (+5.0%) (p=0.042) after 2 months and 4.4 kg (+17.6%) (p=0.044) after 4 months have been recorded. TNFalpha and IL-6 decreased significantly after 2 months (p=0.029, p<0.0001) and 4 months (p=0.026, p=0.006, respectively). ROS decreased significantly after 1 month(p=0.020), 2 months (p=0.022) and 4 months (p=0.022). The QL evaluation showed a mean increase (improved QL) of 14.9% by EORTC QLQ-C30 and 17.3% by EQ-5Dvas after 1 month. Appetite increased of 22.4% after 1 month. Conclusions: At the interim analysis on the first 22 patients the treatment appears effective for the main parameters studied, safe and achieving an optimal compliance by patients. No significant financial relationships to disclose.
Reversible renal failure in the primary antiphospholipid syndrome--a report of two cases.
Authors: D O Sokunbi, F Miller, N K Wadhwa, E P Nord
Journal: Journal of the American Society of Nephrology (1993)

The primary antiphospholipid/anticardiolipin syndrome is a recently described entity wherein multiorgan thrombotic events occur in the absence of objective evidence of systemic lupus erythematosus. The spectrum of renal involvement remains poorly described. Two patients with coagulation abnormalities consistent with the primary antiphospholipid/anticardiolipin syndrome who developed profound renal insufficiency are reported. Striking microangiopathic lesions were documented on renal biopsy. Renal function improved concomitant to the institution of steroid therapy. Reversible renal failure should be added to the spectrum of clinical manifestations of this entity. The diagnosis of the primary antiphospholipid/anticardiolipin syndrome should be contemplated in individuals with unexplained acute renal failure.
Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer
Authors: Giovanna Schiavoni, Fabrizio Mattei, Tiziana Di Pucchio, Stefano M. Santini, Laura Bracci, Filippo Belardelli, Enrico Proietti
Journal: Blood (2000)
Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma.
Authors: G J Rustin, E S Newlands, R H Begent, J Dent, K D Bagshawe
Journal: Journal of Clinical Oncology (1989)

Twenty-five patients with CNS metastases of choriocarcinoma were treated with a regimen incorporating etoposide, methotrexate, and actinomycin (EMA) alternating weekly with vincristine and cyclophosphamide (CO). The dose of methotrexate was increased to 1 g/m2. Eighteen patients presented with CNS metastases, or developed them on inappropriate treatment started elsewhere. Following EMA/CO chemotherapy, three patients died within the first 3 weeks, one is alive with active disease, one died with drug resistance, and 13 (72%) patients are surviving disease-free. Two of seven patients (29%) who developed CNS metastases on treatment with EMA/CO or relapsed after EMA/CO are disease-free after additional chemotherapy and surgery. The contribution toward survival of the craniotomy in six of 18 patients treated initially or early with EMA/CO remains unclear, but was crucial to those patients with drug resistance.
Transcutaneous CO2 monitoring: a new tool to identify spontaneous breathing trial failure during weaning from mechanical ventilation. A pilot cohort study
Authors: Juliana Henao-Brasseur, Jérôme Bedel, Gurkan Mutlu, David Grimaldi, François Brasseur, Virginie Laurent, Gilles Troché, Stéphane Legriel, Jean-Pierre Bedos, Benjamin Planquette
Journal: Intensive Care Medicine (2016)
Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.
Authors: R J Motzer, L Schwartz, T M Law, B A Murphy, A D Hoffman, A P Albino, V Vlamis, D M Nanus
Journal: Journal of Clinical Oncology (1995)

PURPOSE A phase II trial of interferon alfa-2a (IFN) and 13-cis-retinoic acid (CRA) was conducted in patients with renal cell carcinoma (RCC). In vitro studies were performed to investigate potential mechanisms of interaction. PATIENTS AND METHODS Forty-four patients were treated. IFN was given daily at 3 MU and escalated to 6 and 9 MU if tolerated. The dose of CRA was 1 mg/kg/d. The effects of combining CRA and IFN on the proliferation of five RCC cell lines were examined, and retinoid sensitivity was correlated to the expression of retinoic acid receptors. RESULTS Thirteen (30%) of 43 assessable patients achieved a major response (three complete and 10 partial). Responding sites included bone metastases and renal primary tumors. Seven responding patients remain progression-free at 10+ to 19+ months. The response proportion was higher than in our prior experience with IFN, which was 10% in 149 patients. Eleven of 12 renal cancer cell lines were resistant to CRA alone; one, SK-RC-06, showed 90% inhibition of cell growth. CRA augmented the antiproliferative effect of IFN in several IFN-sensitive cell lines, but not in IFN-resistant lines. Northern blot analysis showed that expression of retinoic acid receptor-beta (RAR-beta) was repressed and not induced by retinoic acid in retinoic acid-insensitive RCC lines. However, RAR-beta expression was induced by retinoic acid in SK-RC-06 cells. CONCLUSION IFN and CRA showed antitumor activity in patients with advanced RCC, and the proportion and nature of response suggested CRA added therapeutic benefit to IFN. A phase III randomized trial of IFN plus CRA versus IFN alone and a phase II trial of single-agent CRA have been initiated.